| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |